GlassScriptPhysician profile
Radinka Soto
NPI 1679153084
$810.73
in general payments reported to CMS, 2019-2025
17 companies · $295 in 2025
The $295 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $361 · 2022: $125 · 2024: $29.79 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $325.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $125.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.99 | 2022 | |
| Daiichi Sankyo INC. | $123.21 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $112.43 | 2021 | |
| Janssen Biotech, INC. | $50.38 | 2025 | Carvykti, Tecvayli, Darzalex |
| Merck Sharp & Dohme LLC | $44.28 | 2025 | Keytruda, Lynparza |
| Abbvie INC. | $34.90 | 2025 | |
| Beigene USA, INC. | $28.20 | 2025 | Tevimbra |
| Sobi, INC | $23.71 | 2025 | |
| Emd Serono, INC. | $23.48 | 2025 | |
| Pharmacosmos Therapeutics INC. | $22.59 | 2025 | Monoferric |
| Genentech USA, INC. | $20.08 | 2025 | Phesgo, Tecentriq Hybreza, Itovebi |
| Tersera Therapeutics LLC | $17.34 | 2025 | Zoladex |
| Lilly USA, LLC | $16.76 | 2025 | Verzenio, Jaypirca |
| Adaptive Biotechnologies Corporation | $15.22 | 2024 | Clonoseq |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $14.57 | 2024 | Sylvant |
| Takeda Pharmaceuticals U.S.A., INC. | $13.59 | 2025 | Fruzaqla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Radinka Soto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.